



Attorney Docket No.: 7436.204-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re Application of: Salo et al.

Serial No.: 10/580,101

Group Art Unit: 1646

Filed: May 19, 2006

Examiner: TBD

For: Use of Antibodies to the Gamma 2 Chain of Laminin 5 to Inhibit Tumor Growth and Metastasis

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I hereby certify that the attached correspondence comprising:

1. Petition and Fee For Extension of Time (in duplicate)
2. Response to Notice to File Missing Requirements (in duplicate)
3. Copy of Notice to File Missing Requirements
4. Executed Combined Declaration and Power of Attorney
5. Sequence Listing (28 pages)
6. CRF of Sequence Listing

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

MS: Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


on May 11, 2007

Csaba Attila Szakolczai
(name of person mailing paper)

/Csaba Attila Szakolczai/
(signature of person mailing paper)



UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

pct/1/3

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/580,101	Sirpa Salo	02-1147-US2
INTERNATIONAL APPLICATION NO.		
PCT/US04/38660		
I.A. FILING DATE	PRIORITY DATE	
11/18/2004	11/20/2003	

23650
NOVO NORDISK, INC.
PATENT DEPARTMENT
100 COLLEGE ROAD WEST
PRINCETON, NJ 08540

CONFIRMATION NO. 5078

371 FORMALITIES LETTER



OC000000022290654

Date Mailed: 02/02/2007

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated / Elected Office (37 CFR 1.495).

- Indication of Small Entity Status
- Copy of the International Application filed on 05/19/2006
- Copy of the International Search Report filed on 05/19/2006
- Preliminary Amendments filed on 05/19/2006
- Information Disclosure Statements filed on 05/19/2006
- Biochemical Sequence Listing filed on 05/19/2006
- U.S. Basic National Fees filed on 05/19/2006
- Priority Documents filed on 05/19/2006

- Power of Attorney filed on 12/04/2006

05/18/2007 MKAYPRGH 00000098 141447 10580101

01 FC:2617

65.00 DA

The applicant needs to satisfy supplemental fees problems indicated below.

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date.
- To avoid abandonment, a surcharge (for late submission of filing fee, search fee, examination fee or oath or declaration) as set forth in 37 CFR 1.492(h) of \$65 for a small entity in compliance with 37 CFR 1.27, must be submitted with the missing items identified in this letter.

SUMMARY OF FEES DUE:

Total additional fees required for this application is \$65 for a Small Entity:

- **\$65 Surcharge.**

- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTHS FROM THE DATE OF THIS NOTICE OR BY 32 MONTHS FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web.
<https://sportal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html>

For more information about EFS-Web please call the USPTO Electronic Business Center at 1-866-217-9197 or visit our website at <http://www.uspto.gov/ebc>.

If you are not using EFS-Web to submit your reply, you must include a copy of this notice.

SHELBY J VIGIL

Telephone: (703) 308-9140 EXT 224

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/580,101	PCT/US04/38660	02-1147-US2



Attorney Docket No.: 7436.204-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Salo et al.

Serial No.: 10/580,101

Group Art Unit: 1646

Filed: May 19, 2006

Examiner: TBD

For: Use of Antibodies to the Gamma 2 Chain of Laminin 5 to Inhibit Tumor Growth and Metastasis

RESPONSE TO NOTICE TO FILE MISSING PARTS

Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Notification of Missing Requirements dated February 2, 2007 (a copy thereof is attached hereto), Applicants submit the Declaration for Utility or Design Patent Application signed and dated by Applicants for the above-captioned application.

Applicants also enclose herewith the Sequence Listing for the above-captioned application and a 3.5" floppy disk containing the Sequence Listing. The content of the attached paper entitled "SEQUENCE LISTING" and of the accompanying identically labeled diskette is the same. Furthermore, the information contained in the attached "SEQUENCE LISTING" and the ASCII-encoded file is identical to the information in the specification as originally filed. No new matter is added.

Please charge the required fee, estimated to be \$130.00, with this application and credit any overpayments to Novo Nordisk Inc., Deposit Account No. 14-1447. Please charge any additional fees, should they be required, to Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: May 11, 2007

/Len S. Smith, #43139/
Len S. Smith, Reg. No. 43,139
Novo Nordisk Inc.
Customer Number 23650
(609) 987-5800

Use the following customer number for all correspondence regarding this application.

23650

PATENT TRADEMARK OFFICE